BMY vs. ICLR: Bristol-Myers Squibb vs. ICON Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while ICLR is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas ICON (ICLR) sees a more moderate 943.50K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for BMY.

Bristol-Myers Squibb (BMY) at 18.47% keeps the most of each sales dollar — above its industry’s net margin range — and ICON (ICLR) at 5.26% also retains a top-quartile share.

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bristol-Myers Squibb (BMY) at 1.59 and ICON (ICLR) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ICON (ICLR) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

ICON (ICLR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while ICON (ICLR) at 81.90 sits in the richer quartile — ICLR needs stronger growth or earnings quality to justify the premium.

Both Bristol-Myers Squibb (BMY) at 2.54 and ICON (ICLR) at 1.86 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Bristol-Myers Squibb (BMY) at 5.43 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics